# US 2019/0167667 A1 · Liquid Formulations of Salts of 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]-Piperazine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167667 A1
- Document ID: US20190167667A1
- Status: Published application
- Kind: A1
- Application number: 16/020,799
- Filed: 2018-06-27
- Published: 2019-06-06
- Earliest claimed: 2009-04-24
- Assignees: H. Lundbeck A/S
- Applicants: H. Lundbeck A/S
- Inventors: Svend Treppendahl; Heidi Lopez de Diego
- Web page: https://patentgrep.com/patent/US20190167667A1

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 59/08: Lactic acid
- C07D 295/096: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Liquid formulations of lactic acid addition salts of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine are provided.

## Claims

### Claim 1

A liquid pharmaceutical formulation prepared from:
a salt of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine, the salt being selected from the group consisting of the β form of a DL-lactic acid addition salt, the MH2 form of a L-lactic acid addition salt and the MH2 form of a D-lactic acid addition salt; and
ethanol.

### Claim 2 (depends on 1)

The liquid formulation of claim 1, wherein the salt is the β form of the DL-lactic acid addition salt.

### Claim 3 (depends on 1)

The liquid formulation of claim 1, wherein the salt is the MH2 form of the L-lactic acid addition salt.

### Claim 4 (depends on 1)

The liquid formulation of claim 1, wherein the salt is the MH2 form of the D-Lactic acid addition salt.

### Claim 5 (depends on 1)

The liquid formulation of claim 1, wherein the concentration of the salt is at least 2.5 mg/mL.

### Claim 6 (depends on 1)

A container fitted with a drop aggregate, which container comprises the liquid formulation of claim 1.

### Claim 7 (depends on 6)

The container of claim 6, wherein the salt is the β form of the DL-lactic acid addition salt.

### Claim 8 (depends on 6)

The container of claim 6, wherein the salt is the MH2 form of the L-lactic acid addition salt.

### Claim 9 (depends on 6)

The container of claim 6, wherein the salt is the MH2 form of the D-Lactic acid addition salt.

### Claim 10 (depends on 6)

The container of claim 6, wherein the concentration of the salt is at least 2.5 mg/mL.